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Abstract
Introduction: Acexazolamide is a new derivative of 1,3,4-thiadiazole and acexamic acid.
Materials and methods: In animal experiments, acute toxicity, pharmacological activity and bioavailability of acex-
azolamide were evaluated. Anti-inflammatory activity was assessed on the model of formalin edema of paw and cotton 
pellet granuloma in rats. Assessment of analgesic activity was carried out in a hot plate test in mice, chemical pain 
stimulation of the peritoneum and inflammatory hyperalgesia in rats. The antipyretic activity of acexazolamide was 
evaluated in a model of yeast-induced hyperthermia in rats. The anti-burn activity of acexazolamide was evaluated in 
a thermal skin burn model in rats. Bioavailability of acexazolamide with intragastric administration was determined in 
rabbits. The content of acetaxazolamide in blood plasma was determined by HPLC-MS/MS method.
Results and discussion: DL50 of acexazolamide after intragastric administration to mice was 860.99 (95% CIs, 462.2 
to 1259.8) mg/kg. The anti-inflammatory activity of acexazolamide (21.5 mg/kg) with formalin-induced paw edema 
and fetal granuloma in rats was higher than that of ketoprofen (23.0 mg/kg). ED50 value for analgesic activity with 
acetic acid induced cortex was 24.99 (95% CIs: 15.31–34.68) mg/kg. With thermal stimulation of the paw in mice, 
the ED50 value was 25.56 (95% CIs: 15.13 to 35.98) mg/kg. ED50 value for antipyretic activity was 31.85 (95% CIs: 
19.22–44.47) mg/kg. Acexazolamide (21.5 mg/kg) had a stimulating effect on the regeneration of damaged tissues in 
case of thermal skin burns. Bioavailability of acexazolamide (1 mg/kg) with intragastric administration was 37%.
Conclusion: Acexazolamide has the properties of a non-steroidal anti-inflammatory agent.
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Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are cur-
rently used worldwide (Serhan 2017, Rayar et al. 2017). 
Many NSAIDs cause a number of serious adverse re-
actions, including erosive and ulcerative lesions of the 
gastrointestinal tract, marked changes in the function of 
the liver, kidneys, etc. (Weintraub 2017). The emergence 
of combined NSAIDs with components of other pharma-
cological groups (proton pump inhibitors, H2-histamine 
receptor blockers, prostaglandins, etc.) made it possible to 
reduce the damaging effect on the gastrointestinal mucosa. 
However, such combination drugs had a number of side ef-
fects, non-specific for NSAIDs. The appearance of specific 
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inhibitors of cyclooxygenase-2 could not completely solve 
the problem of the safety of NSAIDs either (Serhan 2017, 
Bjarnason et al. 2018, Grosser et al. 2017). In connection 
with this, it is now urgent to search for new anti-inflamma-
tory drugs with an improved safety profile, including those 
with nonulcerogenicity. The properties of NSAIDs can be 
found in drugs with different chemical structures. Among 
them are acid derivatives (indoleacetic, phenylacetic, 
propionic, salicylic), oxycam, coxibes, and sulfoanilides. 
Thiadiazole derivatives are one of the promising groups for 
creating new drugs (Aday et al. 2018, Aliabadi et al. 2017, 
Djukic et al. 2018, Gomha et al. 2017, Haider et al. 2015, 
Kumari et al. 2017, Matysiak 2015, Pal et al. 2014, Zhong 
et al. 2017), including non-steroidal anti-inflammatory 
medicines (Altıntop et al. 2016, Karki et al. 2015, Sharma 
et al. 2008). It is known that replacement of the carboxyl 
group in the structure of a number of NSAIDs (indome-
thacin, ketoprofen, ibuprofen) with thiadiazole leads to a 
significant decrease in ulcerogenicity without a change in 
the pharmacological activity (Kazaishvili and Popov 2013). 
In addition, presence of thiadiazole nucleus increases lipop-
hilicity of the compounds, thereby improving their pharma-
cokinetic properties, as well as increasing their selectivity 
towards cyclooxygenase-2 (Raj et al. 2018, Altıntop et al. 
2016, Banerjee et al. 2016). In animal experiments, it was 
demonstrated that a number of new derivatives of 1,3,4-thi-
adiazole and organic acids (picoline, oxoethane, propionic 
and others) exhibit properties of non-steroidal anti-inflam-
matory medicines, while with low toxicity and low ulcero-
genicity. However, in the literature there are no references 
to the pharmacological activity of amino acid derivatives 
of thiadiazole. In this regard, it is relevant to study pharma-
cological activity of thiadiazole derivatives with acexamic 
acid, known for its healing and minor anti-inflammatory 
properties (Kim et al. 2013, Popov et al. 2017).
Materials and methods
Experimental animals
A total of 312 male and female Wistar rats, weighing 180–
220 g; 72 male and female SHK mice, weighing 19–23 g; 16 
inbred male Balb/C mice, weighing 21–23 g; 6 male chin-
chilla rabbits weighing 3.2–3.4 kg. The animals were qua-
rantined and acclimatized to the laboratory conditions for 14 
days prior to the start of the experiment. The animals were 
observed for their general health condition and suitability for 
testing during this period. They were maintained at a con-
stant room temperature (22±2 °C) under a 12-h light-dark 
cycle (light on from 8 am to 8 pm). Food and water were 
available ad libitum. The animals were kept under the stan-
dard conditions corresponding to “The Sanitary Regulations 
on Organizing, Equipping and Maintaining Experimental 
Biological Clinics (Vivariums) “No. 1045–73, approved 
by the USSR Chief State Sanitary Officer on 06.04.73 and 
GOST R 53434–2009. All the experiments were carried out 
in compliance with “The European Convention on Protecti-
on of Vertebrates Used for Experimental and Other Scien-
tific Purposes” (Directive 2010/53/EU). All the protocols 
were approved by the Ethics Committee of Tver State Medi-
cal University of the Russian Ministry of Healthcare.
Chemicals and drugs
Acexazolamide (2-(5-aethyl-1,3,4-thiadiazolil) amide of 
acexamic acid) (All-union Scientific Center for the Safe-
ty of Biologically Actice Substances, Staraya Kupavna, 
Moscow region) (Figure 1); Indomethacin (JSC Biosin-
tez, Russian Federation), Ketoprofen (Lek, Slovenia), 
Prednisolone (Agio pharmaceuticals, India), Formalin, 
Acetic acid (Base of chemicals № 1, Russian Federation).
The structure of acexazolamide is confirmed by spec-
tral characteristics, including mass spectra of the I (Figure 
2) and II orders (Figure 3).
The individuality of acexazolamide is confirmed by 
the results of high-performance liquid chromatography.
Synthesis of acexazolamide
A 100 ml of acetonitrile, 12.91 g (0.1 m) of 2-amino-5-et-
hyl-1,3,4-thiadiazole was charged into a three-necked 
flask equipped with a stirrer, thermometer and condenser. 
The mass was stirred, gradually adding 16.65 g (0.1 m) of 
N-acetylaminohexanoic acid chloride; then it was heated 
to boiling. Three 3 hours later, acetonitrile was distilled 
off; 150 ml of distilled water was added, mixed thoroug-
hly, and heated to 80 °C; 15–20 minutes later, the precipi-
tate was filtered off, washed on the filter by distilled water 
to reach pH 6–7 of washing water, and then dried until it 
reached its constant weight at 100–105 °C.
Drug administration
Acexazolamide was administered to the experimental 
animals as an aqueous suspension of Tween-80 intragas-
trically through a metal probe. The volume of the admi-
nistered drug did not exceed 3 ml for rats and 1 ml for 
mice. The concentration of the suspension provided the 
administration of the drug in the required dose at the op-
timum volume.
Acute toxicity evaluation
The groups of 6 mice received doses of 500, 1000, 1500 
and 2250 mg/kg of acexazolamide intragastrically. The 
groups were observed for 14 days and at the end of this 
Figure 1. Chemical structure of acexazolamide (2-(5-aethyl-
1,3,4-thiadiazolil) amide of acexamic acid)
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Figure 3. Mass spectrum (I order) of the ion products of acexazolamide (in the positive ion scan mode, precursor ion m/z 285.2 Da)
Figure 2. Mass spectrum (I order) of the protonated molecule of acexazolamide (in the positive ion scan mode [M+H]+)
period mortality was recorded for each group. DL50 value 
was determined by means of Litchfield and Wilcoxon pro-
bit analysis method modified by V.B. Prozorovsky. The 
hazard class of the studied compound was determined by 
the value of DL50 in accordance with GOST 12.1.007–76 
and the classification of Hodge and Sterner.
Ulcerogenic activity
Acute ulcerogenic activity
The experiments were performed on Wistar rats weighing 
194.4±6.5 g, which were divided into 2 groups of 8 ani-
mals each. Acexazolamide (86.1 mg/kg) and indometha-
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cin (10.0 mg/kg) were administered as water suspension 
intragastrically to the animals which had been kept unfed 
prior to the trial. Three hours later, rats were euthanized; 
and their stomachs were removed and opened along the 
lesser curvature, washed with normal saline to remove 
the contents. Then visual evaluation of the gastric musoca 
condition was carried out. The ulcerogenic activity of the 
compounds studied was evaluated by Pauls index (PI). 
PI = M × N/100
PI – Pauls index; M – the mean number of ulcers in the 
group per one rat; N – the percentage of animals with ulcers.
Subchronic ulcerogenic activity
The subchronic ulcerogenic of acexazolamide and in-
domethacin was determined using Kulkarni’s method 
(1993). The experiments were performed on Wistar rats 
weighing 194.4±6.5 g, which were divided into 2 groups 
of 8 animals each. The rats were intragastrically given 
acexazolamide (21.5 mg/kg) or indomethacin (2.5 mg/
kg) for 4 days. On day 5, the rats were anaesthetized with 
ether and killed by decapitation, then their stomachs were 
removed and opened along the lesser curvature according 
to the method given. The opened stomach was washed 
with normal saline, and damage to the gastric mucosa was 
studied. The ulcerogenic activity of the compounds under 
study was evaluated by Pauls index.
Anti-inflammatory activity
Formalin-induced edema 
The experiments were performed on male and female 
Wistar rats weighing 190–200 g, which were divided into 
groups of 8 animals each. Anti-inflammatory activity 
was assessed by the degree of inhibition of paw edema 
induced by the injection of 0.1 ml of 2% formalin-wa-
ter solution (an edematogenic agent) into the subplantar 
region of the right hind paw of the rat. Edema intensity 
was evaluated by measuring paw thickness of the experi-
mental animal prior to the formalin injecton and at 2, 4, 
6, 24 and 48-h intervals after the administration of for-
malin using an electronic calliper (Vorel 15240, Poland). 
Acexazolamide at different doses (4.3 mg/kg, 21.5 mg/
kg, 43.0 mg/kg and 86.1 mg/kg) and ketoprofen (23.0 
mg/kg) were administered intragastrically 1 h before for-
malin injection.
Cotton pellet granuloma
In this experiment, the effect of acexazolamide and keto-
profen on proliferative and exsudative phases of inflam-
mation was investigated employing cotton pellet granulo-
ma method. The experiments were performed on outbred 
male and female Wistar rats weighing 194.4±6.5 g. The 
rats were anesthetized with diethyl ether. Then cotton 
pellets, weighing 10±1 mg each, were implanted on both 
sides in scapular region under sterile condition. Acexazo-
lamid (21.5 mg/kg) and ketoprofen (23.0 mg/kg) were ad-
ministered daily for seven consecutive days as Tween-80 
suspension. On the 8th day, the rats in all groups were sa-
crificed with a high dose of anesthesia. The pellets sur-
rounded by granuloma tissues were dissected out and kept 
overnight for incubation at 37 °C. The pellets were then 
dried at 60 °C until they reached constant weight. The 
weight of wet pellets was also recorded after sacrificing 
the rats. The average weights of the granulomas were cal-
culated for the rats of the control group and of other trea-
ted groups. The percentage change of granuloma weights 
was calculated for all the test groups by comparing with 
that of the control group.
Analgesic activity
Acetic acid-induced abdominal constrictions
Analgesic activity of acexazolamide was evaluated by 
the test of abdominal writhing induced by acetic acid in 
rats. The experiments were performed on outbred male 
and female Wistar rats weighing 190–200 g, which were 
divided into 6 groups of 8 animals each. The experimen-
tal animals were injected intraperitoneally with 0.1 ml of 
0.75% acetic acid, after which the number of writhings 
was counted for 15 minutes. Acexazolamide (4.3 mg/kg, 
21.5 mg/kg, 43.0 mg/kg and 86.1 mg/kg) and ketoprofen 
(23.0 mg/kg) were administered intragastrically 1 hour 
prior to the injection of acetic acid. The control group ani-
mals received an isotonic sodium chloride solution.
Hot-plate model
The experiments were performed on white non-inbred 
male and female SHK mice weighing 21.5±2.0 g. The 
mice were divided into 6 groups of 8 animals each. The 
experimental animals were placed on a hot aluminum pla-
te at a temperature of 55±0.5 °C for a maximum time of 
30 s. The latent period was recorded before mice showed 
any pain reaction (jumping or licking limbs) 30, 60 and 
120 minutes after the administration of acexazolamide 
(8.6mg/kg, 43.1mg/kg, 86.1mg/kg, 172.2 mg/kg) and ke-
toprofen (46.0 mg / kg).
Randall & Selitto test (paw-pressure test)
Hyperanalgesia was induced by the subplantar adminis-
tration of 0.1 ml of 2% formalin into the rat’s hind paw, 
after which a pain threshold was measured by putting 
pressure on the paw (Randall and Selitto 1957). In the 
Randall & Selitto test, an analgesy-meter with a cone-sha-
ped paw-presser with a rounded tip, which applies a li-
nearly increasing force to the plantar surface of the paw, 
was used. The pain threshold was expressed in grams. 
The moment of a pain reaction was determined by pulling 
the animal’s paw from the analgesimeter. A cut-off value 
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of 300 g was used to prevent damage to the paws. Rats 
were divided into 6 groups of 8 animals in each. Acexa-
zolamide at different doses (4.3, 21.5, 43.0 and 86.1 mg/
kg) and ketoprofen (23.0 mg/kg) were administered intra-
gastrically 2 h after formalin injection.
Antipyretic activity
Yeast-induced hyperthermia model was performed in 
male and female Wistar rats weighing between 204.1±9.2 
g following the method of Teotino et al. (1963). The rats 
were divided into 3 groups of 8 animals each. The rec-
tal temperatures were recorded with an electric thermo-
meter (Citizen CT461C). Hyperthermia was induced by 
subcutaneous injection of yeast (20% water suspension). 
The body temperatures were recorded again 18 h later. 
The rats with the temperature increasing over 1 °C were 
orally administered acexazolamide at different doses 
(8.6mg/kg, 43.1mg/kg, 86.1mg/kg, 172.2 mg/kg) and 
ketoprofen (23.0 mg/kg). The rectal temperatures were 
then recorded 1, 2, 3, 4, 5, 6 and 7 h after the administra-
tion of the drugs.
Active Cutaneous Anaphylactic (ACA) Reactions
Balb/C mice were sensitized by subcutaneous injection 
of 1 ug of ovalbumin in 0.2 ml of normal saline with va-
seline oil. Twenty-one days later, ACA reactions were in-
duced by intradermal injection of 0.05 ug of ovalbumin. 
Simultaneously, 0.25 ml of 1.6% Evans blue solution was 
administered intravenously. Twenty min later, acexazo-
lamide and prednisolone were administrated as well. One 
hour later, 0.05 ug of ovalbumin was injected intrader-
mally into a different skin area. The mice were euthani-
zed 20 min later, after which the area of the spots on the 
skin internal surface caused by Evans blue diffusion was 
measured.
Anti-burn activity
Evaluation of the anti-burn activity of acexazolamide 
was carried out on the model of thermal skin burn in rats. 
A thermal injury was caused with a steel stencil (surface 
area – 225 mm2, incandescence temperature – 240 °C, 
exposure time –14 s, force – 1.6 N). The area of the skin 
defect was daily determined; the burns were evaluated 
visually; the presence and nature of the scab, as well as 
an eschar were examined, and the complete healing of 
the defects was timed. Prior to the beginning of the stu-
dy, and also on the 5th, 10th and 15th day, biopsy of the 
wound edges with the areas of intact skin adjacent to 
the defect area was performed. The histological sections 
were stained with hematoxylin and eosin. With the help 
of an eyepiece micrometer, the biometrics of the sections 
of the resultant tissues was carried out: the thickness of 
the eschar, of the granulation tissue, of the border zone of 
the epithelium, of the leukocyte shaft, and the length of 
the epithelial wedge.
Determination of acexazolamide in blood plasma by 
HPLC-MS/MS method
Determination of acexazolamide in blood plasma of rab-
bits was carried out by HPLC-MS/MS method (Popov 
et al. 2017, Demidova et al. 2018). Chromatography 
was performed with a high-performance liquid chroma-
tograph Agilent 1260 Infinity II (Agilent Technologies, 
Germany) and an analytical column Agilent InfinityLab 
Poroshell 120 EC-C18 2.7 μm 4.6×100 mm. As a mobile 
phase, a mixture of acetonitrile and deionized water at the 
ratio 30:70 with adding 0.1% formic acid in the isocratic 
mode; the flow rate of the mobile phase was 0.6 ml/min. 
For mass spectrometry, an AB SciexQTrap 3200 MD tri-
ple quadrupole mass spectrometer (AB Sciex, Singapore) 
was used with an electrospray ion source (Turbo V with 
a TurboIonSpray probe). Calibration of the mass spectro-
meter was carried out using a test solution of reserpine at 
a concentration of 6.1×10-2 mg/L. For mass spectrometric 
identification of acexazolamide, MRM transitions were 
used in the positive ion recording mode. The MRM values 
were m/z 285.2 → m /z 75.1; m/z 114.2 and m/z130.2. The 
detection limit of acexazolamide in rat plasma was 0.25 
ng/ml. The application range of the procedure was from 1 
ng/ml to 1000 ng/ml. 
Validation of liquid chromatography-tandem mass 
spectrometry (HPLS-MS-MS) method for detection of 
acexazolamide in blood plasma
The HPLS-MS-MS method was validated by the pa-
rameters of selectivity, accuracy, precision, linearity, 
cross-transfer, and stability (EMA 2010).
Evaluation of bioavailability
Pharmacokinetic studies were performed using 6 rabbits 
of the Chinchilla breed. The study was conducted using 
an open, randomized, cross-sectional scheme. The was-
hout period for acexazolamide between the stages was 7 
days. Acexazolamide was administered intravenously at a 
dose of 1 mg/kg in a 0.33% solution of dimexide or intra-
gastrically at a dose of 1 mg/kg in 20 ml of 2% starch mu-
cus. The duration of the monitoring of the concentration 
of acexazolamide in blood plasma exceeded the elimina-
tion half-life period (T1/2) 5 times on average. The blood 
was centrifuged for 10 minutes at a rate of 3000 rpm; the 
resulting blood plasma was stored at -40 °C. Sample pre-
paration was carried out by the method of blood plasma 
protein precipitation by acetonitrile. The maximum con-
centration of acetaxazolamide in the blood (Cmax) and 
the mean time to reach it (tmax) after a single intragastric 
administration to rabbits were determined. The values of 
the area under the pharmacokinetic curve AUC
0 → ∞
 (from 
the moment of administration of the test compound to infi-
nity) and AUC
0 → 36
 (from the moment of administration of 
the test compound to 36 hours) were calculated for intra-
gastric and intravenous administrations. The calculation 
of the bioavailability of the tested drug with intragastric 
administration was carried out according to formula (1):
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Fa – bioavailability (%); AUC i. g. – area under the phar-
macokinetic curve with intragastric administration; AUC 
i.v. – area under the pharmacokinetic curve with intraven-
ous administration.
Statistical analysis methods
For all of the data, the descriptive statistics methods 
were used. The obtained data were checked for norma-
lity of distribution by using Shapiro-Wilk test. The data 
are represented as the mean±standard error of the mean 
(S.E.M.) (in the case of the normal distribution). In cases 
of abnormal distribution, the median and the quartile ran-
ge were calculated. The statistical analysis was performed 
using the Student’s t-test or Mann-Whitney U-test. The 
P-values less than 0.05 were considered significant. The 
statistical analysis was performed using software BioStat 
–2009 software by AnalystSoft Inc.
Results and discussion
Acute toxicity
The mortality of mice after single intragastric administra-
tion of acexazolamide at doses of 500 mg/kg, 1000 mg/
kg, 1500 mg/kg, 2250 mg/kg is shown in Table 1. 
The mortality (in probits) – dose (in logarithms) relati-
onship with a single intragastric administration of acexazo-
lamide in acute toxicity test in mice is shown in Figure 4.
The DL16, DL50, DL84 for mice after intragastric admi-
nistration were 645.7 mg/kg, 861.0 mg/kg (CIs 754.9–
967.1) and 1148.2 mg/kg, respectively.
Basing on the results of the study in accordance with 
GOST 12.1.007-76, acetaxazolamide was classified as a 
3rd hazard class substance, and as moderately toxic sub-
stance according to the classification of Hodge and Sterner.
Ulcerogenic activity
During safety assessment of acexazolamide, the subject of 
study was its ulcerogenic activity at a single (1/5 DL50) 
and subchronic (1/20 DL50) instragastric administration in 
rats compared to that of indomethacinin at equitoxic doses.
Acute ulcerogenic activity
Three hours after a single administration of indometacin 
(10 mg/kg, 1/5 DL50), all the experimental rats develo-
ped destructive changes in the gastric mucosa and serosa. 
Pauls Index (PI) was 11.68.
At a single intragastric administration of acexazolami-
de (86.1 mg/kg, 1/5 DL50) no obvious ulceric defects or 
extensive bleeding in the gastric mucosa were detected. 
Only 35% of the experimental animals had insignificant 
destructive changes. PI in rats which received a single 
dose of acexazolamide was 5.7% of the PI in the compa-
rison group. The values of the Pauls index and the num-
ber of destructive changes in the rats’ stomach at a single 
intragastric administration of indomethacin and acexazo-
lamide at a dose of 1/5 DL50 are shown in Table 2.
The destructive changes (erosion, ulcers and a signifi-
cant number of petechiae) of the gastric mucosa of rats 3 
hours after a single intragastric administration of indome-
thacin (10 mg/kg) are shown in Figure 5.
Three hours after a single intragastric administration of 
acexazolamide (86.1 mg/ kg), no ulcerative defects in the 
stomachs of the experimental rats were registered; there 
were individual erosions and petechiae (Figure 6).
Subchronic ulcerogenic activity
At a subchronic intragastric administration of indometaci-
ne (2.5 mg/kg, 1/20 DL50) on the 5th day of the study, all 
the experimental rats had obvious destructive changes in 
the gastric mucosa.
At an intragastric subchronic administration of acexa-
zolamide (21.5 mg/kg, 1/20 DL50), the destructive chan-
=   . . . .  × 100% 
Table 1.The mortality of mice after single intragastric administration of acexazolamide
Run of tests N Dose (mg/kg) Number of dead mice Mortality rate 
(%)1 day 2 day 3 day 4–14 days Total
Acexazolamide
6 500 0 0 0 0 0 0
6 1000 0 0 4 0 4 66.7
6 1500 0 0 6 0 6 100
6 2250 3 3 0 0 6 100
Table 2.The values of the Pauls index and the number of destructive changes in the rats’ stomach with a single intragastric admin-
istration of indomethacin and acexazolamide at a dose of 1/5 DL50
Run of tests N Single-dose (mg/
kg body wt.)
Number of destructions per 1 rat Average number of 
destructions per 1 rat Pauls indexPetechiae Erosions Ulcers
Acexazolamide 8 86.1 2.12±0.34* 0.25±0.11* 0 2.37±0.44* 0.83*
Indomethacin 8 10.0 8.31±0.91 1.21±0.39 2.16±0.45 11.68±1.25 11.86
Note: The values are expressed as mean±SEM, (n=8). The symbol * indicates statistical significance (P<0.05) compared to the 
control group (indomethacin).
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Figure 4. The mortality (probit) – dose(Lg) relationship with a single intragastric administration of acexazolamide at doses of 500 
mg/kg, 1000 mg/kg, 1500 mg/kg, 2250 mg/kg in acute toxicity test in mice
Figure 5. Destructive changes (erosion, ulcers and a significant number of petechiae) of the gastric mucosa of rats 3 hours after a 
single intragastric administration of indomethacin (10 mg/kg)
Figure 6. Gastric mucosa of rats 3 hours after a single intragastric administration of acexazolamide at a dose of 86.1 mg/kg
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ges were found in 15% of the experimental animals. The 
destructions found were in the form of insignificant pe-
techiae, the average number of which per animal was 
1.33±0.34, which is 88.8% less than that of the animals 
which had received indometacine intragastrically. IP ba-
sed on the overall number of destructions was 0.19 in the 
tested group, which is 98.4% less than that in the compa-
rison group.
The value of the Pauls index and the number of de-
structive changes in the rats’stomach with a subchronic 
intragastric administration of indomethacin and acexazo-
lamide at a dose of 1/20 DL50 are shown in Table 3.
Figure 7 shows the destructive changes (erosion, ulcers 
and petechiae) of the gastric mucosa of rats after subchro-
nic intragastric administration of indomethacin at a dose 
of 2.5 mg/kg (1/20 DL50).
There were no gross destructive changes in the gas-
tric mucosa with subchronic intragastric administration of 
acexazolamide (21.5 mg/kg) (Figure 8).
The data obtained indicate low ulcerogenicity of 
acexazolamide.
Anti-inflammatory activity
At the next stage of experimental research, the anti-in-
flammatory, analgesic and antifebrile effects of acexazo-
lamide were assessed in comparison with the effects of 
non-steroidal anti-inflammatory ketoprofen. On models 
of acute exudative and chronical proliferative inflamma-
tion in rats, acexazolamide was found to have an obvious 
anti-inflammatory effect.
Formalin-induced edema
At an intragastric administration of acexazolamide (21.5 
mg/kg, 1/20 DL50), intensity of formalin-induced edema 
in rats 2 hours after induction of inflammation was 1.4 
times less than that in the control and 1.3 times more 
than in the animals which had received ketoprofen in an 
equitoxic dose. Twenty-four hours after administration of 
formalin, the experimental animals whihc had received 
acexazolamide did not have edema of the paw, whereas in 
the experimental rats which had received ketoprofen, ede-
ma remained and was less than in the control (Table 4).
Table 3. The value of the Pauls index and the number of destructive changes in the stomach in rats with a subchronic intragastric 
administration of indomethacin and acexazolamide at a dose of 1/20 DL50
Run of tests N Dose (mg/kg 
body wt.)
Number of destructions per 1 rat Average number of 
destructions per 1 rat
Pauls index
Petechiae Erosions Ulcers
Acexazolamide 8 21.5 1.33±0.34* 0 0 1.33±0.34* 0.19*
Indomethacin 8 2.5 6.41±0.84 2.11±0.41 3.24±0.44 11.76±1.56 11.76
Note: The values are expressed as mean±SEM, (n=8). The symbol * indicates statistical significance (P<0.05) compared to the 
control group (indomethacin).
Figure 7. Destructive changes (erosion, ulcers and petechiae ) of the gastric mucosa of rats after subchronic intragastric adminis-
tration of indomethacin (2.5 mg/kg)
Figure 8. Gastric mucosa of rats after subchronic intragastric administration of acexazolamide at a dose 21.5 mg/kg
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At an intragastric administration of acexazolamide, the 
highest degree of inhibiting edema of the paw was recor-
ded 2 hours after its induction, whereas at an administra-
tion of ketoprofen it was 4 hours later. 
The dependence of anti-inflammatory effect of acexa-
zolamide (in probits) on a dose (in decimal logarithms) 
in case of a formalin-induced edema of the paw in rats is 
shown in Figure 9.
Based on the analysis of dose-effect relationship bet-
ween anti-inflammatory properties of acexazolamide in 
formalin-induced edema in rats from dose (1/5 DL50, 1/10 
DL50, 1/20 DL50, 1/100 DL50) ED50equaled13.8 (95% CIs: 
8.2–19.4) mg/kg.
Cotton pellet granuloma
Ani-inflammatory properties of acexazolamide were 
proven шт case of chronical proliferative inflammation in 
rats when modelling a cotton pellet granuloma. Reduction 
in both exudative and proliferative inflammation phases 
was registered in a number of tests with using acexazo-
lamide. The exudative reaction in the experimental rats 
which had receieved acexazolamide (21.5 mg/kg, 1/20 
DL50) was 1.2 times less than in the control and 1.1 times 
(р<0.05) than when using ketprofen in an equitoxic dose. 
The proliferative reaction in the experimental rats which 
had received acexazolamide (21.5 mg/kg, 1/20 DL50) was, 
respectively, on average 6.0 and 2.0 times less than that in 
the control and when using ketoprofen (Table 5). 
Analgesic activity
On the models of thermal irritation of the inflammatory 
paw edema in mice (hot-plate test), chemical pain irri-
tation of peritoneum in rats, mechanic irritation of in-
flammatory paw edema in rats, it was determined that 
acexazolamide had a pronounced analgesic effect when 
administered intragastrically.
Table 4. Effects of acexazolamide and ketoprofen on formalin-induced paw edema in rats
Run of tests N Dose (mg/kg body 
wt.)
Paw size before 
inflammation induction 
(mm)
Difference between pawsize (mm) 
4 hours after drug administration
Edema inhibition (%)
Acexazolamide 8 4.3 5.59±0.15 6.95±0.15 27.1
8 21.5 5.62±0.10 6.74±0.10 38.3
8 43.0 5.58±0.10 6.18±0.09 59.9
8 86.0 5.22±0.09 5.74±0.10 62.8
Ketoprofen 8 23.0 5.46±0.06 6.47±0.11 31.2
Formalin (control) 8 – 5.83±0.15 7.40±0.07 –
Figure 9. The dependence of anti-inflammatory effect of acexazolamide (in probits) on a dose (in decimal logarithms) in case of a 
formalin-induced edema of the paw in rats
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Model of mechanic irritation of inflammatory paw 
edema (Randall & Selitto test)
When mechanically irritating the inflammatory paw in 
rats before administration of formalin, the load on the in-
flamed paw causing pain in the animal (week, limb with-
drawal) was on average 122.5 g (p<0.05). However, 3 
hours after administration of formalin, pain limit reduced 
to 66.7 g (p<0.05) on average, which is 45.5% less than 
that before induction of inflammation (Table 6).
When administering acexazolamide (21.5 mg/kg, 1/20 
DL50) and ketoprofen (23.0 mg/kg, 1/20 DL50) intragas-
trically, a significant reduction in the intensity of inflam-
matory hyperalgesia was recorded. Three hours after 
administration of formalin, pain limit in rats which had 
received acexazolamide (21.5 mg/kg, 1/20 DL50) and ke-
toprofen (23.0 mg/kg, 1/20 DL50) reduced to 19.7% and 
21.7% respectively. The assessment of pain limit on an in-
tact paw did not reveal any significant differences before 
and after administration of acexazolamide. 
The dose-effect relationship between analgesic effect 
(in probits) of acexazolamide and a dose (in decimal lo-
garithms) in case of inflammatory hyperalgesia in rats is 
shown in Figure 10.
Based on dose-effect relationship between analgesic 
effect of acexazolamide in the test of mechanic irritation 
of an inflammatory paw in rats and a dose (1/5 DL50, 1/10 
DL50, 1/20 DL50, 1/100 DL50) (Figure 10), ED50 was calcu-
lated, which was 14.0 (95% CIs: 8.3–19.6) mg/kg.
Abdominal constriction test induced by acetic acid 
(writhings)
Analgesic properties of acexazolamide were proven when 
giving rats chemical pain irritation of the peritoneum with 
0.75% vinegar acid solution (0.1 ml/10 g of body mass). 
The test results showed that in the control group the num-
ber of specific nociceptive responses in abdominal con-
striction test was 26.8±1.23 within 15 minutes (Table 7). 
When using acexazolamide (21.5 mg/kg, 1/20 DL50), 
the number of specific nociceptive responses was 51.7% 
less than that in the control. It was also noted that anal-
gesic activity of ketoprofen (23.0 mg/kg, 1/20 DL50) in 
abdominal constriction test in rats had no significant dif-
ference from that of the compound studied.
The dose-effect relationship between analgesic effect 
of acexazolamide (in probits) and a dose (in decimal log-
arithms) in abdominal constriction test induced by acetic 
acid in rats is shown in Figure 11.
Based on the dose-effect relationship between analge-
sic effect of acexazolamide and a dose (1/5 DL50, 1/10 
DL50, 1/20 DL50, 1/100 DL50) in abdominal constriction 
test (Figure 11), ED50 was calculated, which amounted to 
25.0 (95% CIs: 15.3–34.7) mg/kg.
Hot-plate model
The results of hot-plate model test on mice proved anal-
gesic effect of acexazolamide. When placed on 55 °С hot 
surface the experimental mice of the control group started 
showing defensive reflex after 11.3 seconds on average 
(р<0.05). Thirty minutes, 1 and 2 hours after administrati-
on of acexazolamide (43.0 mg/kg, 1/20 DL50) the time be-
fore defensive reflex appeared was, respectively, 17.0%; 
61.9% and 46.4% longer than in the control. However, 
in the hot-plate test 1 and 2 hours after intragastric ad-
ministration of acexazolamide its analgesic activity was, 
respectively, 9.3%, 54.1% and 70.3 % inferior to that of 
ketoprofen (46.0 mg/kg, 1/20 DL50) (Table 8).
Table 5. Effects of acexazolamide and ketoprofen on chronic proliferative inflammation in rats
Run of tests N Dose (mg/kg 
body wt.)
Weight of cotton 
pellet (mg)
Weight of wet 
granuloma (mg)






Acexazolamide 8 21.5 11.55±0.31 139.25±2.43* 16.17±0.39* 123.07±2.37* 4.63±0.38*
Ketoprofen 8 23.0 12.08±0.29 154.0±2.11* 21.33±1.04* 132.66±2.52* 9.25±0.78*
Control 8 – 12.82±0.47 190.87±3.19 40.50±1.29 150.37±3.45 27.67±1.28
Note: The values are expressed as mean±SEM, (n=8). The symbol * indicates statistical significance (P<0.05) compared to the 
control group.
Table 6. Effect of acexazolamide and ketoprofen on pain threshold when mechanically irritating the inflammatory paw in rats





1 h 2 h 3 h 4 h 5 h
Acexazol-amide 8 4.3 125.2±2.7 89.4±3.5* – – – –
8 21.5 127.4±3.5 105.0±3.1* 100.0±2.2* 102.31.7* 103.4±3.2* 103.3±2.7*
8 43.0 134.4±4.1* 114.4±4.1* – – – –
8 86.0 121.7±5.2 128.3±3.7* – – – –
Keto-profen 8 23.0 126.1±3.9 100.5±1.9* 99.1±2.5* 98.7±2.4* 99.2±2.5* 99.1±1.9*
Control 8 – 122.5±6.8 66.7±3.1 69.3±3.1 73.8±2.6 79.6±3.3 84.4±3.4
Note: The values are expressed as mean±SEM, (n=8). The symbol * indicates statistical significance (P<0.05) compared to the 
control group.
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Table 7. Effects of acexazolamide and ketoprofen on the number of specific nociceptive responses (writhings) in abdominal con-
striction test in rats
Run of tests N Dose (mg/kg body wt.) Number of writhing over a period of 15 min Inhibition of pain reaction (%)
Acexazolamide 8 4.3 22.75±1.06* 15.4
8 21.5 13.0±0.72* 51.7
8 43.0 11.87±0.95* 55.9
8 86.0 11.0±0.71* 59.1
Ketoprofen 8 23.0 14.0±0.69* 47.9
Control 8 – 26.9±1.23 –
Note: The values are expressed as mean±SEM, (n=8). The symbol * indicates statistical significance (P<0.05) compared to the 
control group.
Figure 10. Dose-effect relationship between analgesic effect (in probits) of acexazolamide and a dose (in decimal logarithms) in 
case of inflammatory hyperalgesia (Randall & Selitto test) in rats
Figure 11. The dose-effect relationship between analgesic effect (in probits) and a decimal logarithm of a dose of of acexazolamide 
in abdominal constriction test in rats
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The dose-effect relationship between analgesic effect 
of acexazolamide (in probits) and a dose (in decimal lo-
garithms) with thermal irritation of paw in mice in the 
hot-plate test is shown in Figure 12.
Based on dose-effect relationship between analgesic 
effect of acexazolamide on a dose (1/5 DL50, 1/10 DL50, 
1/20 DL50, 1/100 DL50) with thermal irritation of paw in 
mice in the hot-plate test, ED50 was calculating, which 
amounted to 25.6 (95% CIs: 15.1–36.0) mg/kg.
Antipyretic activity
In a yeast-induced hyperthermia model in rats, acexazo-
lamide when administered intragastrically showed obvious 
antipyretic activity. Maximal hyperthermic reaction in rats 
developed 18 hours after administration of 20% suspensi-
on of baker’s yeast; and in the control group it amounted 
to 0.95 °С (р<0.05) on average. Intragastric administration 
of acexazolamide (21.5 mg/kg, 1/20 DL50) and ketoprofen 
(23.0 mg/kg, 1/20 DL50) with a background of maximum 
temperature rise led to reduction of hyperthermic reaction. 
For example, 2 hours after intragastric administration of 
acexazolamide (21.5 mg/kg), the temperature of the test 
rats reduced by 0.83 °С (р<0.05) on average. Yet, anti-
pyretic activity of the tested chemical was inferior to that 
of ketoprofen, 2 hours after using which the hyperthermic 
reaction lowered by 1.0 °С (р<0.05) on average. Further 
observation revealed better antipyretic properties of ket-
oprofen in comparison with that of acexazolamide when 
used in equitoxic doses (Table 9).
The relation of antipyretic effect of acexazolamide (in 
probits) and a dose (in decimal logarithms) in a yeast-in-
duced hyperthermia test in rats is shown in Figure 13.
Based on the dose-effect relationship between anti-
pyretic effect of acexazolamide in the yeast-induced hy-
perthermia test in rats and a dose (1/5 DL50, 1/10 DL50, 
1/20 DL50, 1/100 DL50) (Figure 13), ED50 was obtained, 
amounting to 31.9 (95% CIs: 19.2–44.5) mg/kg.
Antiallergic activity
When given to the experimental mice intragastrically, 
acexazolamide (43.0 mg/kg, 1/20 DL50) reduced reaction 
of active cutaneous anaphylaxis.All ovalbumin-sensibi-
Table 8. Effect of acexazolamide and ketoprofen on the latent period before mice exposed to the hot plate test showed pain reaction
Run of tests N Dose (mg/kg body wt.) Reaction time to pain(s)
0.5 h 1 h 2 h
Acexazolamide 8 8.6 – 13.86±0.63* –
8 43.0 13.8±0.5* 18.3±0.50* 18.3±0.6*
8 86.0 – 19.88±0.70* –
8 172.0 – 24.04±1.02* –
Ketoprofen 8 46.0 14.9±0.6* 24.4±0.70* 27.2±1.0*
Control 8 – 11.8±0.8 11.3±0.90 12.5±0.4
Note: The values are expressed as mean±SEM, (n=8). The symbol * indicates statistical significance (P<0.05) compared to the 
control group.
Figure 12. The dose-effect relationship between analgesic effect (in probits) and a decimal logarithm of a acexazolamide dose in 
the hot-plate test 
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Table 9. Effects of acexazolamide and ketoprofen on intensity of hyperthermic reaction in rats in a yeast-induced hyperthermia test
Run of tests N Dose (mg/kg 
body wt.)
Rectal temperature 18 h after yeast injection, °C
0 h 2 h 3 h 4 h 5 h 6 h 7 h
Acexazol-amide 8 4.3 37.93±0.04* 37.27±0.08* – – – – –
8 21.5 37.91±0.07* 37.08±0.07* 36.88±0.06* 36.95±0.06* 37.04±0.07* 36.98±0.05* 37.06±0.04*
8 43.0 37.91±0.05* 36.81±0.07* – – – – –
8 86.0 37.96±0.06* 36.81±0.07* – – – – –
Keto-profen 8 23.0 37.88±0.05 36.88±0.05* 36.85±0.03* 36.67±0.05* 36.69±0.02* 36.69±0.03* 36.83±0.03*
Control 8 – 37.66±0.11 37.86±0.04 37.61±0.04 37.51±0.03 37.51±0.05 37.51±0.04 37.53±0.03
Note: The values are expressed as mean±SEM, (n=8). The symbol * indicates statistical significance (P<0.05) compared to the 
control group.
Figure 13. The relation of antipyretic effect (in probits) and a decimal logarithm of a dose of acexazolamide in yeast-induced hy-
perthermia test in rats
lized experimental mice developed local allergic reacti-
on on the 21st day of latent sensibilization period when 
the antigen was adminiatered intradermally. In the mice 
which had received prednisolone at a dose of 0.5 mg/
kg, the size of the test spot was 53.9±1.7 mm2, which on 
average is 81.2% less than the area of the control colored 
spot of the skin. The group of animals which had received 
acexazolamide intragastrially (43.0 mg/kg, 1/20 DL50) 
also demonstrated a lowered reaction of active cutaneous 
anaphylaxis (Table 10).
The area of the control spots in mice was 314.8±8.6 
mm2, whereas intragastric administration of acexazolami-
de at a dose of 43.0 mg/kg (1/20 DL50) reduced the area of 
coloured skin spots by 36.4% in comparison with that in 
the control (Figure 14).
Results of the experimental study revealed antiallergic 
activity of acexazolamide. Inhibition of the reaction of 
active cutaneous anaphylaxis in mice when administering 
acexazolamide (43.0 mg/kg) was on average by 44,8% 
lower than that of prednisolone (0.5 mg/kg).
Anti-burn activity
Considering the fact that in the chemical structure of acexa-
zolamide there is a fragment of acexamic acid, having pro-
nounced reparative properties, the next stage of the study 
was to evaluate the anti-burn activity of acexazolamide.
The results of the study showed that daily intragastric 
administration of acexazolamide to rats (21.5 mg/kg, 1/20 
DL50) (p<0.05) reduced terms of full epithelialization of 
the burn. Its full epithelialization with cicatrization in the 
rats of the experimental group happened on average on 
the 13.3th day (p<0.05), which was 1.3 times (p<0.05) fas-
ter than that in the rats which had received normal saline 
per os. Starting on average from the 4th day (p<0.05), the 
area of the burn in the experimental group was positively 
smaller than that in the control (Figure 15).
Daily intragastric administration of acexazolamide at 
a dose of 21.5 mg/kg activated processes of regeneration 
and growth of new connective tissue and epithelium over 
the defected zone.
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Table 10. Effect of acexazolamide and prednisolone on the intensity of reaction of active cutaneous anaphylaxis (ACA) in mice
Run of tests N Dose (mg/kg body wt.) Area of coloured spot, mm2 Inhibition of ACA, %
Experiment Control
Acexazolamide 8 43.0 (i.g.) 200.2±8.0* 314.8±8.6 36.4
Prednisolone 8 0.5 (i.p.) 53.9±1.7* 286.9±8.0 81.6
Note: The values are expressed as mean±SEM, (n=8). The symbol * indicates statistical significance (P<0.05) compared to the 
control group (prednisolone).
Figure 15. Area of wound defect at different periods after the thermal burn in rats receiving acexazolamide (21.5 mg/kg)
Figure 14. The reaction of active cutaneous anaphylaxis in mice when administering acexazolamide at a dose of 43.0 mg/kg: on the 
left – an experimental spot, on the right – a control spot
On the 5th day of the experiment, the rats of the con-
trol group had developed a tight eschar from necrotized 
tissue, curdled plasm and degeneratively modified leuko-
cytes 310.8±10.1 µm thick. A thick 113.0±5.9 µm leu-
kocyte crust consisting of 2 layers spread over the whole 
wound. The surface had variously shaped cells with hy-
perchromatic nuclea. The bottom layer consisted of cell 
elements of a typical structure with no signs of degene-
ration. Local granulation tissue formed slowly and consi-
sted of macrophages, neutrophilic leukocytes and histo-
cytes. Individual vertical capillaries of various diameters 
were located in granulation tissue. Deep layers of the 
wound had horizontal poorly differentiated fibroblasts of 
typical structure. The fibroblasts were pointed in diffe-
rent directions in the 662.2±21.4 µm thick granulated tis-
sue, which had edema with leukocytal infiltration. Epit-
helium regeneration (5–6 layers of cells) had a wedge 
shape 405.5±15.2 µm long. Epithelium hypertrophy on 
the boundary of intact skin was ill-defined (114.0±8.8 
µm) (Table 11).
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The rats which received acexazolamide intragastrically 
(21.5 mg/kg, 1/20 DL50) on a daily basis on the 5th day de-
veloped a 218.6±8.5 µm thick eschar which is 29.8% less 
than that in the control. The thickness of the leukocytal crust 
did not have definable changes from that of the control. The 
leukocytal crust consisted of fibrin and degeneratively mo-
dified leukocytes. The granulation tissue was well-develo-
ped and had multiple parallel vertical blood vessels in its 
structure. Its thickness was 966.2±11.7 µm, which is 45.9% 
more than that in control. Also there was active proliferation 
of fibroblasts. Developed granulation tissue was a perfect 
breeding ground for new epithelium which along the defect 
edges had grown into the neighbouring tissues. The zones 
of ingrowths were marked with high quantity of cells with 
mitosis figures. Hypertrophied epithelium was 200.2±5.4 
µm on the boundary, which is 75.6% more than that in rats 
of the control group. The length of epithelium regenerate 
(699.3±27.2 µm) was 72.5% more than that in control.
On the 10th day of observation, the control group ani-
mals had a thin leukocytal necrotic layer. The 206.0±5.8 
µm thick eschar was partially fragmented and tightly sea-
led with the neighbouring tissues. The leukocytal crust 
was a 76.2±2.5 µm thin line. It had fagocytal macropha-
ges and neutrophilic leukocytes of normal structure. The 
granulation tissue fully covered the burn and had a typical 
structure and thickness of 832.7±11.3 µm. Its surface lay-
er had vertically oriented blood vessels. Granulation had 
a layer of fibroblasts chaotically-oriented around the ves-
sels and much collagen fiber. Granulation tissue rearran-
ged into new connective tissue. Most of the wound surfa-
ce was covered with newly-produced epithelium of 5–6 
layers of cells. The regenerate length was 650.±50.1 µm. 
Basal membrane of the epithelium regenerate was even. 
On the edges it formed growths into the neighbouring tis-
sues. The epithelium thickness on the boundaries of the 
defect was 141.8±3.6 µm (Table 12).
Figure 16 shows the histological picture of the wound 
defect in the rats of the control group on the 10th day after 
thermal damage to the skin.
The animals which daily received acexazolamide 
intragastrically (21.5 mg/kg, 1/20 DL50) had epitheli-
um regenerate of a substantial length – 992.5±8.1 µm, 
which was 52.6% more than that in the control. In the 
structure of regenerative epithelium, vertical differen-
tiation with skin derivatives was found. On the edges 
of the defect, epithelium was 232.5±10.0 µm thick, 
which was 64.0% more than that in the control. The 
eschar thickness was 60.0% less in comparison with 
that in the control. The eschar was fragmentally present 
in the center of the defect. Under it was a leukocytal 
crust 16.6±4.5 µm thick, which was 78.2% less than 
that in the control. In small patches of the wound not 
covered with epithelium, partial differentiation of gra-
nulated tissue was noted. On its surface was a layer 
of vertically oriented blood vessels. Most of the de-
fect was filled with horizontally oriented fibroblasts. 
Among fibroblasts there were multiple collagen fiber 
bundles. Granulation tissue had significant thickness of 
(1309.8±19.7 µm against 832.7±11.3 µm in control). 
On the edges of the wound defect, young connective 
tissue was being formed (Figure 17).
The rats which had daily received acexazolamide 
intragastrically (21.5 mg/kg, 1/20 DL50) developed a 
scar of a typical structure over the wounded surface 
on the 15th day. Regenerate resembled a thin strip dif-
ferentiated by layers. The defect was filled with matu-
re connective tissue with horizontally oriented fibro-
blasts and multiple collagen fiber bundles. All over the 
new epithelium, the basal membrane formed multiple 
growths into the neighbouring tissue with signs of hair 
follicle and oil gland formation (Figure 18 B). The 
majority of the experimental group animals developed 
organo-specific regenerate with all characteristics of 
normal skin (Figure 18 A).
Daily intragastric administration of 21.5 mg/kg of 
acexazolamide promotes epithelization of the 3rd degree 
burns in rats.
Table 11. Morphological changes after thermal burn of rat skin (day 5) 
Run of tests N Dose (mg/kg 
body wt.)
Thickness (µm) Length of 
regenerate (µm)Eschar Leukocyte infiltration Granulation tissue Epithelium at the edge
Acexazolamide 8 21.5 218.2±8.5* 112.3±3.0 966.2±11.7* 200.2±5.4* 699.3±27.2*
Control 8 – 310.8±10.1 113.0±5.9 662.2±21.4 114.0±8.8 405.5±15.2
Note: The values are expressed as mean±SEM, (n=8). The symbol * indicates statistical significance (P<0.05) compared to the 
control group.
Table 12. Morphological changes after thermal burn of rat skin (day 10) 
Run of tests N Dose (mg/kg 
body wt.)
Thickness (µm) Length of 
regenerate (µm)Eschar Leukocyte infiltration Granulation tissue Epithelium at the edge
Acexazolamide 8 21.5 81.3±4.0* 16.6±4.5* 1309.0±19.7* 232.5±10.0* 992.5±8.1*
Control 8 – 206.0±5.8 76.2±2.5 832.7±11.3 141.8±3.6 650.5±50.1
Note: The values are expressed as mean±SEM, (n=8). The symbol * indicates statistical significance (P<0.05) compared to the 
control group.
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Bioavailability of acexazolamide
The analysis of the results of the experimental study sho-
wed that 1 minute after intravenous (i.v.) administration 
of acexazolamide (1 mg/kg), its content in blood plasm of 
rabbits was 20323±1136 ng/ml. The value obtained was 
equal to the theoretical concentration calculated by means 
of dividing the quantity of the medicine administered to 
the experimental rabbits by the assumed volume of circu-
lating blood. At intragastric (i.g.) administration of 1 mg/
kg maximum content of acexazolamide was 806.8±65.6 
ng/ml, which is 96% less than the maximum concentrati-
on at its itravenous administration (Table 13).
Based on the results of the pharmacokinetic study, the 
graphs of concentration/time relation (pharmacokinetic 
curves) were made for intravenous (Figure 19) and intra-
gastric (i.g.) administration (Figure 20).
At intravenous administration, reduction in acexazo-
lamide concentration in blood plasma of the experimental 
rabbits had a 2-phase character (α and β phases). The α 
phase was characterized by quick concentration decrease 
in the tested medicine in blood plasma within the first 45 
minutes, perhaps on the account of its redistribution in 
tissue (allocation phase). The β phase was marked by a 
slow decrease in concentration of acexazolamide. Thir-
ty-six hours after intravenous administration of the tested 
medicine, its content in blood plasma was reaching its 
low quantitation limit. The area under the pharmacokine-
tic curve AUC
0→36 





was 2.96±1.59%, which proved 
Figure 16. Histological picture of the wound defect in rats of 
the control group, 10th day after thermal injury of skin. Coloured 
with haeatoxylin and eosin. Zoom 400×
Figure 17. Histological picture of the wound defect in rats 
which received acexazolamide intragastrically (21.5 mg/kg), the 
10th day after thermal injury of skin. Coloured with haeatoxylin 
and eosin. Zoom 400×
Figure 18. Histological picture of the wound defect in rats which received acexazolamide intragastrically (21.5 mg/kg) (A) and in 
the control group (B), the 15th day after thermal injury of skin. Coloured with hameatoxylin and eosin. Zoom 400× 
A B
43
Table 13. Pharmacokinetic parameters of acexazolamide (1 mg/kg) in rabbit
Parameter Acexazolamide (i.g.) Acexazolamide (i.v.)
Сmax(ng/ml) tmax(h) Сmax(ng/ml)
1 860 1.385 21454
2 890 1.323 20621
3 804 1.258 19108
4 784 1.317 21411
5 701 1.299 20560
6 802 1.487 18784
Mean 806.8 1.345 20323
Gmean 804.6 1.343 20296
SD 65.6 0.081 1136
CV, % 8.1 6.02 5.6
Median 803 1.32 20590.5
min 701 1.258 18784




Figure 20. Pharmacokinetic curve of acexazolamide (1 mg/kg) observed in rabbit plasma (i.g.)
Figure 19. Pharmacokinetic curve of acexazolamide (1 mg/kg) observed in rabbit plasma (i.v.)
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adequate length of monitoring the tested drug in blood 
plasma (Table 14).
Based on the results of the pharmacological study con-
ducted, a value of absolute bioavailability of acexazo-
lamideat was calculated with intragastric administration 
of 2% starch mucus to rabbits at a dose of 1 mg/kg. This 
indicator is on average 37%. 
Thus, the new amino acid derivative of thiadiazol un-
der study possesses definable anti-inflammatory, anti-
pyretic and analgesic properties combined with low ul-
cerogenicity, which makes it promising as a non-steroidal 
anti-inflammatory medicine.
Table 14. The areas under the pharmacokinetic curve (AUC
0 → 36 
and AUC
0 → ∞
), with intravenous injection of acexazolamide at a 










1 15642 16373 4.67
2 12761 13216 3.56
3 13168 13307 1.05
4 15061 15766 4.69
5 11905 12196 2.44
6 12650 12821 1.35
Mean 13531 13946 2.96
Gmean 13466 13863 2.54
SD 1478 1701 1.59
CV, % 10.9 12.20 53.90
Median 12965 13262 3.00
Min 11906 12196 1.05





DL50 of acexazolamide at intragastrtic administration in 
mice was 861.0 (95% CIs, 754.9–967.1) mg/kg, which 
in accordance to GOST 12.1.007–76 makes it possible to 
classify it as a 3rd hazard class chemical and as a modera-
tely toxic substance in accordance with the classification 
of Hodge and Sterner.
Ulcerogenicity of acexazolamide at single intragastric 
administration in rats at a dose of 1/5 DL50 (86.1 mg/kg) 
was 14 times (р<0.05) lower than that of indometacine in 
an equitoxic dose (10.0mg/kg). At its subchronic adminis-
tration, the ulcerogenicity Pauls Index for acexazolamide 
at a dose of 1/20 DL50 (21.5 mu/kg) was 0.19, which was 
61.9 times (р<0.05) lower than that of indometacine in an 
equitoxic dose (2.5mg/kg).
On the models of acute exudative and chronical polife-
rative inflammation in rats, acexazolamide demonstrated 
its pronounced anti-inflammatory effect. On formalin-in-
duced edema, the index of ED50 at intragastric administra-
tion was 13.8 (95% CIs: 8.2–19.4) mg/kg. Anti-inflam-
matory effect of acexazolamide at a dose of 21.5 mg/kg 
(1/20 DL50) at acute exudative inflammation was on aver-
age 1.25 times (р<0.05) higher than that of ketoprofen in 
an equitoxic dose (23 mg/kg). At chronical inflammatory 
reaction (cotton pellet granuloma), inhibition of polifera-
tive phase under the influence of acexazolamide at a dose 
of 21.5 mg/kg (1/20 DL50) was approximately 1.28 times 
(р<0.05) higher than that of ketoprofen in an equitoxic 
dose (23 mg/kg).
On models of mechanic irritation of inflammatory paw 
edema and abdominal constriction test in rats, thermal ir-
ritation of mice paws, acexazolamide exercised its anal-
gesic effetc at intragastric administration. At mechanic 
irritation of inflammatory paw edema in rats, ED50 was 
14.0 (95% CIs: 8.3–19.6) mg/kg. ED50 for analgesic ef-
fect in case of writhings caused by vinegar acid was 25.0 
(95% CIs: 15.3–34.7) mg/kg. At thermal irritation of 
mice paws, ED50 was 25.6 (95% CIs: 15.1–36.0) mg/kg. 
On models of mechanic irritation of inflammatory paw 
edema and abdominal constriction test in rats, analgesic 
effect of acexazolamide at a dose of 1/20 DL50 (21.5 mg/
kg) had no significant difference from that of ketoprofen 
in an equitoxic dose (23 mg/kg).
Antipyretic activity of acexazolamide at a dose of 1/20 
DL50 (21.5 mg/kg) at yeast-induced hyperthermia in rats 
was approximately 1.2 times (р<0.05) lower than that of 
ketoprofen in an equitoxic dose (23 mg/kg). ED50 was 
t31.9 (95% CIs: 19.2–44.5) mg/kg. At intragastrically 
administered to mice at a dose of 1/20 DL50 (43.0 mg/
kg), acexazolamide reduced reaction of active cutaneous 
anaphyaxis 1.57 times (р<0.05) in comparison with that 
of the control.
Daily intragastric administration of acexazolamide at 
a dose of 1/20 DL50 (21.5 mg/kg) reduced healing period 
of 3rd degree burns in rats 1.3 times (р<0.05) on average. 
Histological structure of regenerate in the experimental 
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animals which had received acexazolamide was close to 
that of normal skin on the 15th day.
Bioavailability of acexazolamide with intragastric ad-
ministration to rabbits at a dose of 1 mg/kg as an aqueous 
suspension averaged 37%.
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